Development of LY2334737, an Oral Gemcitabine Prodrug for Continuous Administration. Perspectives for the Therapy of Mature T-Cell and NK-Cell Lymphomas. Hematol Meeting Rep 2009, 3 (1). https://doi.org/10.4081/hmr.v3i1.533.